Light Mode
$27.44 ↓ -0.35 (-1.26%) Trading Down from the previous close of $27.79
-1.11 (-3.84%) / 6M
Momentum, market sentiment, and recent alerts
BEAM reads neutral: price sits above one of the two key moving averages, the 12-month move is +20.5%.
Earnings, valuation, and balance sheet
Company profile and competitor comparison
Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.